Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia

Affiliations

¹ University of Texas, MD Anderson Cancer Center, Houston, TX.
² The Ohio State University Medical Center, Columbus, OH.
³ University of California Irvine, Irvine, CA.
⁴ Stanford University School of Medicine, Stanford, CA.
⁵ Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
⁶ Weill Cornell Medical College, New York, NY.
⁷ University of California San Diego, Moores Cancer Center, San Diego, CA.
⁸ Norton Cancer Institute, Louisville, KY.
⁹ Willamette Valley Cancer Institute & Research Center/US Oncology Research, Eugene, OR.
¹⁰ Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milano, Italy.
¹¹ Sarah Cannon Research Institute, Nashville, TN.
¹² Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA.
¹³ Peter MacCallum Cancer Centre and St. Vincent's Hospital, Melbourne, Australia.

William G Wierda et al. Br J Haematol. 2019 Jul.

. 2019 Jul;186(1):184-188.

doi: 10.1111/bjh.15791. Epub 2019 Feb 10.

¹ University of Texas, MD Anderson Cancer Center, Houston, TX.
² The Ohio State University Medical Center, Columbus, OH.
³ University of California Irvine, Irvine, CA.
⁴ Stanford University School of Medicine, Stanford, CA.
⁵ Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
⁶ Weill Cornell Medical College, New York, NY.
⁷ University of California San Diego, Moores Cancer Center, San Diego, CA.
⁸ Norton Cancer Institute, Louisville, KY.
⁹ Willamette Valley Cancer Institute & Research Center/US Oncology Research, Eugene, OR.
¹⁰ Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milano, Italy.
¹¹ Sarah Cannon Research Institute, Nashville, TN.
¹² Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA.
¹³ Peter MacCallum Cancer Centre and St. Vincent's Hospital, Melbourne, Australia.

No abstract available

Keywords: chronic lymphocytic leukaemia; genomic risk factors; ibrutinib; tumour debulking; tumour lysis syndrome risk.

Publication types